Evidence map›Paper›PMID 22967833›Full record

Trial reportAmerican journal of obstetrics and gynecology2012

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.

Steve N Caritis, Shringi Sharma, Raman Venkataramanan, Gary D Hankins, Menachem Miodovnik, Mary F Hebert, Jason G Umans, Thomas Benedetti, Donald Mattison, Anne Zajicek and 3 more

Abstract readClinical Trial
In one paragraph

Trial report in American journal of obstetrics and gynecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.BJOG : an international journal of obstetrics and gynaecology · 2016
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Steve N CaritisDepartment of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Shringi Sharma
Raman Venkataramanan
Gary D Hankins
Menachem Miodovnik
Mary F Hebert
Jason G Umans
Thomas Benedetti
Donald Mattison
Anne Zajicek
Dawn Fischer
Aimee Jackson
Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetrical-Fetal Pharmacology Research Units Network

Funding

UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Georgetown-Howard Universities Center for Clinical and Translational Science (GHUUL1TR000101 · NCATS · GEORGETOWN UNIVERSITY · PI MELLMAN, THOMAS A, VERBALIS, JOSEPH G · 2012 to 2015
$19.3M
Georgetown-Howard Universities Center for Clinical and Translational Science (GHUUL1RR031975 · NCRR · GEORGETOWN UNIVERSITY · PI MELLMAN, THOMAS A, VERBALIS, JOSEPH G · 2010 to 2011
$14.6M
Pregnancy and Drug Metabolizing Enzymes and TransportersU10HD047905 · NICHD · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI CARITIS, STEVE N · 2004 to 2014
$9.7M
UW Obstetric-Fetal Pharmacology Research UnitU10HD047892 · NICHD · UNIVERSITY OF WASHINGTON · PI EASTERLING, THOMAS R, HEBERT, MARY F · 2004 to 2014
$9.4M
Training in Basic and Clinical Pharmacology in PregnancyT32HD071859 · NICHD · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI CARITIS, STEVE N, VENKATARAMANAN, RAMAN · 2012 to 2016
$722k
NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR000101NCRR NIH HHS 1 UL1RR031975NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR031975NICHD NIH HHS T32 HD071859NICHD NIH HHS U10 HD047892NICHD NIH HHS U10HD047892NICHD NIH HHS U10 HD047905NICHD NIH HHS U10HD047905
6 · The paper itself

Abstract

objectiveThe purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. STUDY

designSixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery.

resultsThe half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection.

conclusionThe apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

Indexed as

17 alpha-Hydroxyprogesterone CaproateAdultBiological TransportBody Mass IndexFemaleFetal BloodHumansHydroxyprogesteronesPlacentaPregnancyProgestinsYoung Adult17 alpha-Hydroxyprogesterone CaproateHydroxyprogesteronesProgestins

Identifiers

PMID22967833
PMCPMC3586341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.